DrugDashboards

trametinib

trametinib · TRAMETINIB DIMETHYL SULFOXIDE .5 mg/1 · Tablet, Film Coated · GlaxoSmithKline Manufacturing SpA

NDC 12064-0021-00 · 57000 TABLET, FILM COATED in 1 DRUM · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00078-1105-15) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$173.30per unit
middle half $168.74$179.65 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $173.30
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 5 · prior auth 98% · step therapy 0% · qty limit 77%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of trametinib (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
GlaxoSmithKline Manufacturing SpATRAMETINIB DIMETHYL SULFOXIDE .5 mg/1Jul 15, 2026Sep 2, 2026
GlaxoSmithKline Manufacturing SpATRAMETINIB DIMETHYL SULFOXIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharma Stein AGTRAMETINIB DIMETHYL SULFOXIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharma Stein AGTRAMETINIB DIMETHYL SULFOXIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharmaceuticals CorporationTRAMETINIB DIMETHYL SULFOXIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Novartis Pharmaceuticals CorporationTRAMETINIB DIMETHYL SULFOXIDE 2 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "trametinib — NDC 12064-0021-00," retrieved September 3, 2026, https://drugdashboards.com/drug/12064002100.

Free to cite with attribution — see how the data is put together.